Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04711200
Other study ID # P150941J
Secondary ID
Status Not yet recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date September 2022
Est. completion date September 2025

Study information

Verified date April 2022
Source Assistance Publique - Hôpitaux de Paris
Contact Saskia Oro, MD
Phone 0149812536
Email saskia.oro@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare severe cutaneous adverse reactions (SCARs) to drugs. To date, no curative drug has demonstrated with a good level of evidence its ability to promote SJS and TEN healing and could contribute to earlier reepithelialisation. Mesenchymal stroma cells (MSCs) therapy represents a new therapeutic approach. eg, in patients with cardiovascular diseases, neurological diseases, renal transplantation, lung diseases as acute respiratory distress syndrome. Recently, MSCs have been proposed in both burn wound healing with a significantly decrease of the unhealed burn area and in cutaneous radiation. Moreover, MSCs have immunomodulation properties potentially effective in refractory acute and chronic graft versus host disease (GVHD) by improving thymic function and induction of Tregs. Indeed, MSCs are able to migrate to inflamed tissues after stimulation by pro-inflammatory cytokines and to modulate the local inflammatory reactions. MSCs have also demonstrated their ability to promote tissue remodelling, angiogenesis and immunomodulation through either differentiation or secretion of several growth factors such as VEGF, basic FGF and various cytokines. Therefore, combining their immunomodulation effect and secretion of soluble factors involved in wound repair, MSCs might be valuable as a cell therapy strategy for promoting cutaneous healing in SJS-TEN syndrome and subsequently decrease the morbi-mortality.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 15
Est. completion date September 2025
Est. primary completion date September 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Patients aged from 18 to 75 years-old - Admission less than 10 days after onset of the reaction - Patient with confirmed SJS-TEN diagnosis hospitalized in the department of Dermatology or intensive care medicine - At least 10 % of detachable-detached body surface area at any time during the first 10 days after the index date (date of the first symptoms of the disease) - Written consent from patient or trustworthy person or legal representant or family member - Affiliated to a social security scheme Exclusion Criteria: - Pregnant or breastfeeding women - History of malignant disease within the past ten years and or presence of metastasis - Positive serology for HIV - Active infection for hepatitis B or C - Decompensated cardiac failure - Uncontrolled epilepsia - Previous history of allogenic bone marrow transplantation - Participation in other interventional drug research - Patient deprived of liberty by a judicial or administrative decision or under the protection of justice - Any psychological, familial, sociological or geographical condition potentially hampering compliance with the research protocol and follow-up schedule - Patient under tutorship or curatorship - Patient under psychiatric care according to art. L1121-6 CSP

Study Design


Intervention

Drug:
Adipose derived stromal cells intravenously injected
2×10^6/kg of Adipose derived stromal cells A single injection at D0 (performed maximum three days post-admission).

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

References & Publications (5)

Chung HM, Won CH, Sung JH. Responses of adipose-derived stem cells during hypoxia: enhanced skin-regenerative potential. Expert Opin Biol Ther. 2009 Dec;9(12):1499-508. doi: 10.1517/14712590903307362. Review. — View Citation

Creamer D, Walsh SA, Dziewulski P, Exton LS, Lee HY, Dart JK, Setterfield J, Bunker CB, Ardern-Jones MR, Watson KM, Wong GA, Philippidou M, Vercueil A, Martin RV, Williams G, Shah M, Brown D, Williams P, Mohd Mustapa MF, Smith CH. U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol. 2016 Jun;174(6):1194-227. doi: 10.1111/bjd.14530. — View Citation

Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. Lancet. 2017 Oct 28;390(10106):1996-2011. doi: 10.1016/S0140-6736(16)30378-6. Epub 2017 May 2. Review. Erratum in: Lancet. 2017 Oct 28;390(10106):1948. — View Citation

Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008 Jan;128(1):35-44. Epub 2007 Sep 6. — View Citation

Roux S, Leotot J, Chevallier N, Bierling P, Rouard H. [Mesenchymal stromal cells: Biological properties and clinical prospects]. Transfus Clin Biol. 2011 Feb;18(1):1-12. doi: 10.1016/j.tracli.2011.01.001. Epub 2011 Mar 1. French. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Safety : Observation of at least one adverse effect Day 10
Primary Efficacy : Rate of complete or almost complete reepithelialisation Day 7 after infusion
Secondary Rate of observed and predicted death by the SCORTEN at one month
Secondary Duration of hospitalisation according to our historical cohort related to BSA involved Month 12
Secondary Duration of hospitalisation according to our historical cohort related to onset of the disease Month 12
Secondary Duration of hospitalisation according to our historical cohort related to SCORTEN Month 12
Secondary Duration of each mucous membranes healing ie.(buccal, nasal, genital, eyes) at Month 12
Secondary Rate of sepsis at Month 12
Secondary Rate of intensive care transfer at Month 12
Secondary Rate of sequelae at Month 12
Secondary Th1/Th2 immune response in the peripheral blood of the patients after injection at Day 0, Day 10, Month 1
Secondary Evaluation of expression profile of Th1/Th2 associated chemokines and anti-inflammatory chemokines in the peripheral blood after injection at Day 0, Day 10, Month 1.
Secondary Epidermal chimerism study on healed skin biopsy at 1 month
Secondary Cutaneous re-epithelialization rate at D5, D10 and D15 post-infusion according to the percentage of cutaneous BSA re-epithelialized in comparison to maximal cutaneous detachable-detached BSA observed. at Day 5, Day 10 and Day15
See also
  Status Clinical Trial Phase
Completed NCT03265613 - Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis Phase 1/Phase 2
Completed NCT02274428 - Phase 1 Clinical Trial of PNEUMOSTEM® Treatment in Premature Infants With Intraventricular Hemorrhage Phase 1
Recruiting NCT04626583 - Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells Phase 1
Active, not recruiting NCT03874572 - Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia/Dry Mouth Phase 1
Recruiting NCT04785027 - Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined With AD-MSCs in Psoriasis Phase 1/Phase 2
Recruiting NCT05602116 - ASC - Autism Study Phase 1
Recruiting NCT04918706 - Allogeneic MSC Treatment for Pulmonary Emphysema Phase 2
Completed NCT03392311 - Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis Phase 1/Phase 2
Recruiting NCT05204329 - Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease Early Phase 1
Recruiting NCT05595681 - Effect of Mesenchymal Stem Cells on Healing of Foot Ulcers in Diabetes Patients. Phase 1
Not yet recruiting NCT03745417 - Efficacy and Safety of Expanded UCMSCs On Patients With Moderate to Severe Psoriasis Phase 1/Phase 2
Enrolling by invitation NCT03876197 - Mesenchymal Stem Cells for Radiation-induced Xerostomia Phase 1/Phase 2
Terminated NCT04371393 - MSCs in COVID-19 ARDS Phase 3
Completed NCT04275024 - Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment and PSORI-CM01 Granule in Psoriasis Patients N/A